chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from an 81 year old female patient referring to herself. Concurrent condition and medical history were not reported. On 03-AUG-2015 the patient was vaccinated with PNEUMOVAX 23 (lot # L003228, expiration date 30-JUL-2016, dose was unknown) intramuscularly for prevention of pneumococcal disease. On 03-AUG-2015, with a few minutes after the vaccination, the patient experienced continuous pain at injection site. The patient stated that the pain had made it difficulty for her to lift things and move her arm. The patient sought medical attention by calling the provider. The patient stated provider gave her MOTRIN (Dosage unknown) for the pain, but after more than a month, she continued to have pain and difficulty with her arm (not recovered). Additional information is not expected as the physician asked not to be contacted and lack of contact information.
A report has been received from a health professional concerning a 1 year old female student who had been receiving FLUMIST Quadrivalent. FLUMIST Quadrivalent started on 07-OCT-2014. Sixteen month hold patient accidentally received FLUMIST Quadrivalent. The outcome of the event of inadvertent administration of FLUMIST Quadrivalent to a 16 month old patient is unknown. The report was consider4ed to be non-serious.
throat starts getting dry; sore arm; This is a spontaneous report from a Pfizer sponsored program from a contactable consumer (patient). A female patient of unspecified age received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on 10Feb2021 as single dose for COVID-19 immunization. Medical history and concomitant medications of the patient were not reported. Patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unspecified date as single dose for COVID-19 immunization. On an unspecified date in Feb2021 at around 2-3am, patient throat started getting dry and she experienced sore arm all through night until morning when got up had sharp pain under her arm. Patient asked what type of pain reliever she could take. Outcome of the events were unknown.  Follow-up attempts completed. No further information expected.
Information has been received from a registered nurse concerning a 9 year old female who in December 2005, was vaccinated with a dose of MMR II. Subsequently the patient experienced lymphadenopathy. Unspecified medical attention was sought. There was no product quality complaint. Additional information has been requested.
low grade fever, 101-102; inc irritability, dec appetite-tense fontanelle-aseptic meningitis; 48 hr p/ administration of vax; hospitalized 2 days;
This spontaneous case, was initially received on 11-Aug-2017 from other health professional, concerning a 21-year-old, adult female patient. The patient's medical history and concomitant medication was not reported. On 09-Aug-2017, the patient was administered with FLUCELVAX QIV (dose: (reported as less than 0.5 ml). batch number: 195214, route of administration, anatomical location, expiry date: not reported). Partial dose of vaccine was administered as the patient could not tolerate the pain. The outcome of the event pain during injection was resolved. The reporter assessed this case as non-serious. Non-significant case correction received 11-Aug-2017: Batch no. (195214) was captured in the case form and narrative was amended accordingly.
I have both Tinnitus and Rotary Vertigo, the Vertigo is mostly at night when I turn over.
Pt vaccinated with 1st dose of vax JUL89 & 2nd dose JAN90 between 1st & 2nd dose pt developed vaginal yeast infect & rash;
Patient reported feeling very lethargic, developed fever, swelling, redness and heat at injection site (more than expected). Patient reported symptoms lasting for 4 days.
1. Chronic systolic heart failure She is clinically stable at this time. Time course and clinical picture suggest possible vaccine associated myocarditis. Continue GDMT including furosemide, lisinopril, metoprolol and spironolactone. She will also be seen in heart failure clinic.   2. Left ventricular thrombi Possibly secondary to myocarditis with hypercoagulable state as noted above. Continue warfarin. Repeat echocardiogram in about 6-8 weeks.
Pt had a fever the day after her vaccine.  She took tylenol and it worked for the first couple doses and then did not bring it down after that.  The highest it reached was 100.9.  She's never gotten a fever after a vaccine before.  She was concerned enough to call her tele-nurse through her insurance and they advised her to alternate the tylenol with motrin.  After taking motrin she hasn't had any further issues an feels fine today 11/5.  She just wanted the event reported
w/in 48 hrs p/vax pt exp an inject site rxn; had swelling from the groin to knee w/redness & warmth on PE; dx cellulitis; tx included augmentin & Atarax;
Took Anthrax #2 and developed arthralgias of shoulders and neck with increased liver enzymes. Right axillary node swollen and left ankle rash. Anthrax follow up questionnaire received on 08/21/2003: "Vaccine recipient is unknown if he recovered from the adverse event.  Vaccine recipient's current employment status is full duty.  No work days were missed as a result of this event.  The vaccine recipient was not evaluated by a physician or health care provider for this event.  Vaccine recipient did not receive any further Anthrax shots since the reported event.  OTHER COMMENTS:  On two different physicals since 03/18/2000, I have been shown to have a low positive for Lupus on the blood test."
Patient presented for administration of 2nd vaccine. Registration clerk presented that patient did not bring his COVID-19 Vaccine Record Card. Patient ID given to look up details for previous vaccine. During this time, patient sat down in the chair and proceeded to tell the nurse that he received his last Moderna Vaccine several weeks ago. During review, determined that patient received Pfizer Vaccine (Lot # ER8729, Expiration Date 7/31/2021, Intramuscular Injection in Right Upper Arm, Dose 1)  on 4/9/21. Patient then stated "I can't remember what vaccine I got last time". Patient was asked to sit for 15 minute observation period. Patient had no adverse reactions. Explained to patient that he would not need an additional vaccine after this one. Patient verbalized understanding. Spoke with patient at 18:00. He stated "I'm fine other than my arm is a little sore".
Became fussy on 10/13/14, 10/14/14 tired and more sleepy decreased oral intake 10/15/14 developed emesis, came to ED, 10/16/14 diagnosis with transverse colon intussusception and was reduced.
severely elevated high blood pressure; severe ongoing headache; neck and costo-sternal pain and muscle stiffness
hot flashes, 99-100 fever, sore throat, extreme neck stiffness, joints ache, insomnia, dry mouth, diarrhea, beginning 8JUN93 w/worsening s/s beginning 14JUN93;
A day after the second shot of the vaccine, I felt fatigued and had a headache for 3 days. Starting day 4, itchiness started and would not go away. Still itchy, when I am not on medication.
adverse event after my booster; really bad hives/aren't seeming to go away; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (really bad hives/aren't seeming to go away) and VACCINATION COMPLICATION (adverse event after my booster) in a 47-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031H21A, 93967G and 011D21A) for COVID-19 vaccination.     No Medical History information was reported.   On 20-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 31-Jul-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Dec-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Dec-2021, the patient experienced URTICARIA (really bad hives/aren't seeming to go away). On an unknown date, the patient experienced VACCINATION COMPLICATION (adverse event after my booster). The patient was treated with FEXOFENADINE HYDROCHLORIDE (ALLEGRA [FEXOFENADINE HYDROCHLORIDE]) for Adverse event, at an unspecified dose and frequency and HYDROXYZINE HCL for Adverse event, at a dose of 25 mg. At the time of the report, URTICARIA (really bad hives/aren't seeming to go away) had not resolved and VACCINATION COMPLICATION (adverse event after my booster) outcome was unknown.            No concomitant medication reported. No treatment information was provided
R arm red and blistery at Varivax inj site. Valtrex 500 BID x 5 days Denavir cream.
develops Covid19 confirmed by nasal swab test 'Covid rapid test'.; develops Covid19 confirmed by nasal swab test 'Covid rapid test'.; she got sick in 2021; This is a spontaneous report received from non-contactable reporter(s) (Consumer or other non HCP) from product quality group and a sales representative. The reporter is the patient.  A 30 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administration date 05May2021 (Lot number: EW0167) at the age of 29 years as dose 2, single and administration date 14Apr2021 (Lot number: ER8731) as dose 1, single for covid-19 immunisation. Relevant medical history included: "Hypothyroidism" (unspecified if ongoing), notes: Hypothyroidism, for which she takes Levothyroxine.; "Covid" (unspecified if ongoing), notes: if covid prior vaccination: Yes. Concomitant medication(s) included: LEVOTHYROXINE taken for hypothyroidism. The following information was reported: VACCINATION FAILURE (medically significant) with onset Feb2022, outcome "unknown", COVID-19(medically significant) with onset Feb2022, outcome "recovered" and all described as "develops Covid19 confirmed by nasal swab test 'Covid rapid test'."; MALAISE (non-serious) with onset 2021, outcome "recovered", described as "she got sick in 2021". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (Feb2022) positive, notes: Nasal Swab test.AE treatment:10 day course of cephALEXin 500 MG.Patient should have received the 3rd dose, however with dose 1 and dose 2 she got sick in 2021, and for that reason she did not want to receive the third dose.  No follow-up attempts are possible. No further information is expected.
Intense pain at injection site; Severe throat swelling, code blue, taken to ER, hospitalized; Facial swelling; Rapid heartbeat; Dizziness; Shortness of breath; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 55-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Co-suspect products included epinephrine for injection site pain, heartbeats increased, throat swelling and facial swelling.   Concurrent medical conditions included hearing aid wearer. Concomitant products included cetirizine hydrochloride (Zyrtec) and famotidine (Pepcid).   On 11th February 2022, the patient received the 2nd dose of Shingrix. On an unknown date, the patient started epinephrine at an unknown dose and frequency. On 11th February 2022, immediately after receiving Shingrix, the patient experienced injection site pain (serious criteria hospitalization and clinically significant/intervention required), throat swelling (serious criteria hospitalization and clinically significant/intervention required), facial swelling (serious criteria hospitalization and clinically significant/intervention required) and heartbeats increased (serious criteria hospitalization and clinically significant/intervention required). In February 2022, the patient experienced dizziness (serious criteria hospitalization and clinically significant/intervention required) and shortness of breath (serious criteria hospitalization and clinically significant/intervention required). In February 2022, the outcome of the injection site pain, throat swelling and heartbeats increased were recovered/resolved. On an unknown date, the outcome of the facial swelling, dizziness and shortness of breath were not recovered/not resolved.   It was unknown if the reporter considered the injection site pain, throat swelling, facial swelling, dizziness, shortness of breath and heartbeats increased to be related to Shingrix.     Linked case(s) involving the same patient:  US2022AMR034721  Additional details were provided as follows: The patient self-reported this case. The patient stated that she was now taking Zyrtec, Oral Steroids, Benadryl, and Pepcid. The patient had received a dose of Shingrix and as soon as the vaccine was injected, she experienced intense pain at the injection site and within 10 minutes developed a rapid heartbeat, severe throat swelling, and facial swelling.  The patient stated that a code blue was called, and she was taken to the emergency department and received a dose of Epinephrine and intravenous steroids.  The patient stated she continued to have facial swelling and less than 2 weeks after receiving Shingrix, epinephrine and intravenous steroids, the patient was experiencing dizziness and becomes short of breath walking up stairs. It was unknown if the reporter considered the dizziness and shortness of breath to be related to Epinephrine and intravenous steroids.  The reporter consented to follow-up. The case was linked with case US2022AMR034721, reported by same reporter.
injection site has been sore; This case was reported by a consumer via call center representative and described the occurrence of injection site pain in a 18-year-old female patient who received Men B NVS (Bexsero) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 20th November 2020, the patient received the 1st dose of Bexsero and Bexsero Pre-Filled Syringe Device. On 20th November 2020, less than a day after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced injection site pain. On an unknown date, the outcome of the injection site pain was not recovered/not resolved.   It was unknown if the reporter considered the injection site pain to be related to Bexsero and Bexsero Pre-Filled Syringe Device.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The case was reported by the mother for her daughter. The patient received dose of Bexsero in left arm. After receiving dose of Bexsero and Bexsero Pre-Filled Syringe Device the patient experienced injection site soreness. The customer does not have any additional details for this adverse event. The reporter did not consent to follow up.
This spontaneous report was received from a physician and from a support services director via company representatives and refers to a patient of unknown age and gender. The patient's pertinent medical history, drug reactions or allergies and concomitant medications were not reported. On 22-OCT-2015, the patient was vaccinated with a dose of an improperly stored GARDASIL 9 (strength: 0.5 ml) lot # L014198 and expiration date: 05-SEP-2017 (dose, anatomical location and route of administration were not reported). No adverse effects were reported. The dose of the vaccine was exposed to a temperature excursion (date unspecified): lasting for 544 hours, with the lowest recorded temperature of 29 degrees Fahrenheit (-1.66 degrees Celsius). The vaccine was stored in a refrigerator. There was no product quality complaint involved. This is one of several reports received from the same reporter. Additional information has been requested.
Patient states that after first dose of Moderna (27JAN2021 Lot 028L20A) she developed scratchy throat and hives which she had planned for due to history of same. She pre-dosed with benadryl. Today, she pre-dosed with Benadryl 50mg at ~ 1815. She received her vaccination at 1920, at ~1940 she began to have sensation of tongue swelling, coughing, difficulty breathing and hives. VS at time were BP 170/100, HR 92, RR 24 and wheezing. She was coughing when asked to speak or take deep breaths.  FF/EMT on scene evaluated and treated with epinephrine 0.3mg IM. After 2-3 minutes patient begins to breath easier and can speak in full sentences. Hives on upper extremities have receded and overall, patient states that she is feeling better. EMS was called and patient was transported to local ER for further evaluation/treatment.
My eyes have been really dry lately. It has caused me to blink much harder; My eyes have been really dry lately. It has caused me to blink much harder; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 20 year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 07Oct2021 14:30 (Batch/Lot number: unknown) at the age of 20 years as dose 1, single for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRY EYE (non-serious), OCULAR DISCOMFORT (non-serious) all with onset 11Oct2021 12:00, outcome "not recovered" and all described as "My eyes have been really dry lately. It has caused me to blink much harder". Therapeutic measures were taken as a result of dry eye, ocular discomfort.  Additional information: Facility type vaccine: Pharmacy or Drug Store. No other vaccine in four weeks. No other medications in two weeks. No covid prior vaccination. No covid tested post vaccination. No Known allergies. No other medical history.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
pt recv vax 12FEB97 & 24FEB97 pt exp a sore throat, malaise & a non-specific, itchy rash;
This spontaneous report was received from an immunization official referring to 7 patients of unknown ages and gender. The patients' medical history, concurrent conditions and concomitant medications were not reported. Between 13-AUG-2015 and 01-JAN-2016 the patients were vaccinated with improperly stored (Oka/Merck) VARIVAX lot # K007976 expiration date 03-JUN-2016 (strength, dose and administration route were not reported). No adverse events were reported and no product quality complaint was involved. This is one of several reports received from the same reporter. Additional information has been requested.
Information has been received from a registered nurse, via a company representative, concerning a 17 year old female patient who on an unspecified date was vaccinated at school, with a dose of GARDASIL (lot # not provided). Concomitant therapy included "a number of other vaccines" (therapy unspecified) on the same day. The nurse reported that the patient had "a significant fainting episode" (details not provided). After an unknown duration of time, the patient regained consciousness. At the time of this report, the outcome of events was unknown. This is one of two reports received from the same source (0711USA04213). The patient sought unspecified medical attention. No further information is available.
Dose #1 Pfizer 2/25/2021 lot # EN6198 Patient tested COVID + 12/30/2022, hospitalized at a local Medical Center. Patient died in this hospital on 1/4/2023 from Covid 19 pneumonia and respiratory failure.  hospitalized 112/30/2022-1/4/2023.
This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a female patient of unknown age. No information was provided regarding concomitant medications, concurrent conditions or medical history. On or about 13-OCT-2014, the patient was inoculated with ZOSTAVAX at a pharmacy as recommended for routine adult health maintenance and for the prevention of shingles (dose, route, and lot # not provided). The vaccine did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. In 2016, the patient was treated by a physician for a persistent and severe vesicular rash, which was diagnosed as herpes zoster or shingles. As a direct and proximate result of ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. The outcome of the events was unknown.  Causality assessment was related. Additional information has been requested.
High blood pressure; Felt bad; Weakness; Upset stomach; Diarrhea; Chills; This spontaneous case was reported by a consumer and describes the occurrence of HYPERTENSION (High blood pressure), MALAISE (Felt bad), ASTHENIA (Weakness), ABDOMINAL DISCOMFORT (Upset stomach) and DIARRHOEA (Diarrhea) in a 76-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 041L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 26-Jan-2021, the patient experienced HYPERTENSION (High blood pressure), MALAISE (Felt bad), ASTHENIA (Weakness), ABDOMINAL DISCOMFORT (Upset stomach), DIARRHOEA (Diarrhea) and CHILLS (Chills). On 26-Jan-2021, MALAISE (Felt bad), ASTHENIA (Weakness), ABDOMINAL DISCOMFORT (Upset stomach), DIARRHOEA (Diarrhea) and CHILLS (Chills) had resolved. At the time of the report, HYPERTENSION (High blood pressure) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Jan-2021, Blood pressure measurement: 200/100 (High) high blood pressure of 200 over 100. On an unknown date, Blood pressure measurement: 134/95 (High) blood pressure down to 134/95.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.
Administered 1st dose of Pfizer 0.3ml vaccine. Pt mentioned feeling nervous and having a phobia of needles. During 15min observation period pt stated she felt a slight irritation on the outer lining of lips and felt dizzy. Administered 50mg of oral diphenhydramine soln, BP measurement 150/52, continued to monitor pt. No trouble breathing reported, pt reported feeling better. Monitored pt for additional 25 minutes, BP decreased and pt stated feeling better and no issueS breathing. Advised pt mother to visit hospital if s/sx worsened and to continue to monitor minor for any other adverse effects. Pt stabilized BP and HR, and felt better.
Reports that on day of receiving first dose of HPV vaccine (6/21/21) felt dizzy and "weaker than I've ever felt." Also reports painless, swollen, nonerythematous, nonpruritic lesion roughly 1.5 cm in diameter below right eye. Sx resolved by next day.
My upset stomach began on the evening after the injection.  I took Imodem which helped but did not stop the loose & constant stools. About 24 hours later I started bleeding from my bowels which continues.